Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corporation (Nasdaq: SWKH) is a life science focused specialty finance company that regularly reports on its financial performance, portfolio activity, and strategic transactions. As a provider of non-dilutive financing to small- and mid-sized commercial-stage healthcare companies, SWK’s news flow centers on its finance receivables portfolio, royalty monetization activity, and developments within its pharmaceutical development services operations.
Readers of this SWKH news page can expect updates on quarterly and annual financial results, including GAAP net income, segment-level non-GAAP metrics, effective yields on finance receivables, and changes in book value and tangible finance book value per share. The company frequently issues press releases in connection with its earnings reports and hosts conference calls to discuss its corporate and financial results.
SWK’s news also highlights portfolio transactions such as new term loans, expansions of existing credit facilities, sales and monetizations of royalty portfolios, and resolutions of nonaccrual positions or workout situations. Announcements have included the monetization of royalty assets, special dividends funded by those monetizations, and updates on loan payoffs and recoveries.
In addition, the company discloses strategic and corporate events, including its Agreement and Plan of Merger with Runway Growth Finance Corp., as well as updates on its pharmaceutical development subsidiaries. Investors following SWKH news gain insight into how SWK manages its life science finance portfolio, how non-GAAP measures relate to reported results, and how strategic transactions may affect stockholders. For those tracking the specialty finance and healthcare capital markets, this page offers a focused stream of company-issued information and regulatory news related to SWK Holdings Corporation.
Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), will participate in the virtual Partnership Opportunities in Drug Delivery (PODD) 2021 Conference on October 28-29, 2021. The company aims to engage with pharmaceutical executives about its innovative formulation technologies, Peptelligence® and ProPerma®, which facilitate oral delivery of challenging compounds. Enteris is advancing several programs leveraging these technologies, some already in late-stage clinical development. The conference emphasizes the growing interest in oral biologics delivery.
Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), will participate in the AAPS 2021 PHARMSCI 360 Conference from October 17-20, 2021 at the Pennsylvania Convention Center, Philadelphia. The conference offers in-person and virtual meeting options. Enteris will showcase its innovative drug delivery technologies, Peptelligence® and ProPerma®, during meetings with pharmaceutical executives. These technologies support oral delivery of complex drug compounds and are part of the company's CDMO services, which have gained significant interest from the pharmaceutical sector.
Enteris BioPharma, a subsidiary of SWK Holdings (SWKH), has completed a successful Phase 1 clinical trial for its optimized Peptelligence oral tablet formulation of leuprolide. The trial, involving 22 patients, demonstrated that the oral formulation can safely deliver higher doses, achieving blood concentrations comparable to traditional injection methods. Enteris' proprietary Peptelligence platform enables the oral delivery of peptides and small molecules, enhancing patient compliance. The company plans to advance this product for diseases responsive to GnRH agonists.
Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has received the 2021 Best of Boonton Award in the Pharmaceutical Company category, marking its third consecutive win. The award recognizes Enteris' growth from a startup to an industry leader in oral delivery of therapeutics since 2013. CEO Rajiv Khosla highlighted the company's resilience during the COVID-19 pandemic, citing a facility expansion and key milestones in partnerships. Enteris is committed to addressing unmet clinical needs using its proprietary technologies, Peptelligence® and ProPerma™.
SWK Holdings Corporation (SWKH) reported strong financial results for Q2 2021, with total revenue reaching $22.3 million, a significant increase from $7.9 million in Q2 2020. The growth is attributed to a $10.3 million rise in the Pharmaceutical Development segment and a $4.1 million increase in Finance Receivables. Adjusted net income rose to $17.2 million, up from $4.0 million a year prior. The company also announced a $5.0 million share repurchase program and formed a Strategic Review Committee to explore options for maximizing shareholder value.
Silicon Labs (NASDAQ: SLAB) has finalized the sale of its Infrastructure & Automotive business to Skyworks Solutions (NASDAQ: SWKH) for $2.75 billion in cash. This divestiture marks a pivotal shift, allowing Silicon Labs to focus solely on secure, intelligent wireless connectivity, a critical area in the growing global IoT market. The company plans to return approximately $2.0 billion to shareholders post-transaction through special dividends and share buybacks, with net proceeds estimated at $2.3 billion after costs.
SWK Holdings Corporation (Nasdaq: SWKH) announced advancements during the first half of 2021 across its portfolio. The company emphasized a strong recovery in life sciences, attributing growth to its unique financing structures for small and mid-sized firms. Highlights include a $10 million milestone from Cara Therapeutics for Oral KORSUVA development and ongoing progress at Enteris BioPharma. Notable transactions include a $9.5 million financing with Trio Healthcare and a $5 million royalty deal with Ideal Implant. SWK recorded a 1.5x multiple on invested capital from borrower repayments.
SWK Holdings Corporation (Nasdaq: SWKH) has authorized a stock repurchase program of up to $5.0 million, effective until March 15, 2022. This initiative, executed through a 10b5-1 trading plan, aims to enhance shareholder value amidst ongoing strategic reviews. CEO Winston Black stated that the buyback represents an optimal use of capital during this period. The program could start as early as July 15, 2021, depending on market conditions and trading constraints.
Enteris BioPharma, a biotechnology company and a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), is hosting a webinar titled "Key Considerations for HPAPI Oral Drug Product Development" on June 29, 2021, at 1 p.m. ET. The event will feature experts Josh Stephens and Angelo Consalvo, discussing trends in outsourcing the manufacture of solid oral drugs with high potency active pharmaceutical ingredients (HPAPI). The webinar aims to provide insights into selecting a contract development and manufacturing organization (CDMO) and address the rising demand in this sector.
SWK Holdings Corporation (Nasdaq: SWKH) announced that its subsidiary, Enteris BioPharma, received a $10 million milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the licensing of Peptelligence technology for Oral KORSUVA. Enteris will retain $3.9 million from this payment. This payment follows the completion of an End-of-Phase 2 Meeting with the FDA regarding Oral KORSUVA for chronic kidney disease. Enteris has previously received milestone payments totaling $5 million and is eligible for more as development milestones are achieved.
FAQ
What is the current stock price of Swk Hldgs (SWKH)?
What is the market cap of Swk Hldgs (SWKH)?
